Ovarian Endometrioid Adenocarcinoma

Curated

civic

Ovarian Endometrioid Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 37show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 26 trials (9 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 22 trials (10 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 20 trials (6 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 11 trials (6 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall_molecule 10 trials (8 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 5 trials (5 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Ovarian Endometrioid Adenocarcinoma	2	Observed	clinicaltrials	graph →

Ovarian Endometrioid Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 37show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

26 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

22 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

20 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

11 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall_molecule

10 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cediranibsmall molecule

5 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

5 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Chemotherapy

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Letrozolesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma

Ovarian Endometrioid Adenocarcinoma studied in …STUDIED_INderived10 of 73show all (up to 200)
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 73 trials mapped (31 active)	—	—	Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05281471Phase 3 · recruiting Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · condition mapped ALIAS · 73 trials mapped (31 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →

Ovarian Endometrioid Adenocarcinoma studied in …STUDIED_INderived10 of 73show all (up to 200)

→ studied in

NCT07504588Phase 2 · recruiting

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT05276973Phase 1 · active not recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT05920798Phase 1/Phase 2 · active not recruiting

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT04575935Phase 3 · recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT02101775Phase 2 · active not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT05950464Phase 1 · recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT02142803Phase 1 · active not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT02839707Phase 2/Phase 3 · active not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT04034927Phase 2 · active not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped CURATED_BROADER · 73 trials mapped (31 active)

—

Observed

→ studied in

NCT05281471Phase 3 · recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · condition mapped ALIAS · 73 trials mapped (31 active)

—

Observed